Valuation: Eli Lilly and Company

Capitalization 920B 784B 732B 689B 1,268B 83,330B 1,385B 8,545B 3,315B 39,280B 3,452B 3,379B 143,308B P/E ratio 2025 *
44.9x
P/E ratio 2026 * 32.5x
Enterprise value 945B 805B 752B 708B 1,303B 85,589B 1,423B 8,777B 3,405B 40,345B 3,546B 3,471B 147,194B EV / Sales 2025 *
14.9x
EV / Sales 2026 * 12.2x
Free-Float
99.81%
Yield 2025 *
0.58%
Yield 2026 * 0.65%
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.80%
1 week+1.70%
Current month-4.46%
1 month+0.22%
3 months+36.02%
6 months+25.40%
Current year+33.10%
More quotes
1 week 977.12
Extreme 977.12
1,031.56
1 month 977.12
Extreme 977.12
1,111.99
Current year 623.78
Extreme 623.78
1,111.99
1 year 623.78
Extreme 623.78
1,111.99
3 years 302.14
Extreme 302.14
1,111.99
5 years 161.78
Extreme 161.78
1,111.99
10 years 64.18
Extreme 64.18
1,111.99
More quotes
Manager TitleAgeSince
Chief Executive Officer 57 2016-12-31
President - -
Director of Finance/CFO 48 2024-09-08
Director TitleAgeSince
Director/Board Member 65 2004-12-31
Director/Board Member 69 2009-03-31
Director/Board Member 53 2011-12-11
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.80%+1.70%+30.21%+182.67% 920B
+0.75%+4.78%+44.31%+17.70% 510B
-0.29%-1.22%+28.81%+35.46% 395B
-0.35%+1.90%+25.12%+3.01% 340B
-1.12%-1.09%+28.43%+17.93% 278B
-0.45%-1.48%+20.24%+22.49% 254B
+1.30%+0.58%-1.67%-10.09% 249B
+0.45%+3.73%-57.41%-31.49% 224B
+0.11%-3.68%+17.41%+17.19% 171B
-2.28%-0.68%+31.08%+36.20% 149B
Average -0.01%+0.45%+16.65%+29.11% 349.14B
Weighted average by Cap. +0.42%+1.07%+22.26%+57.74%
See all sector performances

Financials

2025 *2026 *
Net sales 63.58B 54.16B 50.59B 47.6B 87.64B 5,759B 95.74B 591B 229B 2,714B 239B 234B 9,903B 76.3B 65B 60.72B 57.13B 105B 6,911B 115B 709B 275B 3,258B 286B 280B 11,885B
Net income 20.4B 17.38B 16.23B 15.27B 28.12B 1,848B 30.72B 189B 73.49B 871B 76.54B 74.93B 3,177B 28.05B 23.89B 22.32B 21B 38.66B 2,540B 42.24B 261B 101B 1,197B 105B 103B 4,369B
Net Debt 24.95B 21.25B 19.85B 18.68B 34.39B 2,259B 37.57B 232B 89.88B 1,065B 93.6B 91.63B 3,886B 10.94B 9.32B 8.7B 8.19B 15.08B 991B 16.47B 102B 39.41B 467B 41.04B 40.18B 1,704B
More financial data * Estimated data
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
Employees
47,000
More about the company
Date Price Change Volume
25-12-12 1,027.51 $ +1.80% 3,275,239
25-12-11 1,009.38 $ +1.58% 4,516,960
25-12-10 993.64 $ +1.16% 2,966,270
25-12-09 982.22 $ -1.54% 2,569,724
25-12-08 997.59 $ -1.26% 3,088,557

Delayed Quote Nyse, December 12, 2025 at 04:00 pm EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
1,027.51USD
Average target price
1,075.74USD
Spread / Average Target
+4.69%
Consensus

Quarterly revenue - Rate of surprise